Aerin Medical, Inc. (“Aerin”), a medical technology company focused on improving the quality of life for patients suffering with nasal airway disorders through the development and commercialization of disruptive minimally-invasive treatments, announced that it closed on a $50 million non-dilutive term loan agreement with CRG LP, a healthcare focused investment firm.
Merck has reached a deal to acquire Peloton Therapeutics, and its Phase 3-ready kidney cancer drug, for $1.05 billion.
LivaNova PLC, a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time.
Preliminary results from patients treated with BPX-601 who underwent lymphodepletion with cyclophosphamide plus fludarabine to be presented
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in second quarter of 2019